{
    "2020-04-08": [
        [
            {
                "time": "",
                "original_text": "健帆生物一季度净利预增三至五成",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "一季度",
                        "净利",
                        "预增",
                        "三至五成"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "健帆生物(300529.SZ)：一季度净利预增30%-50%",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "300529.SZ",
                        "一季度",
                        "净利",
                        "预增",
                        "30%-50%"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "健帆生物：预计一季度盈利1.68亿-1.94亿元，同比增长30%-50%",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "一季度",
                        "盈利",
                        "1.68亿-1.94亿元",
                        "同比增长",
                        "30%-50%"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【东北医药崔洁铭】健帆生物（300529）年报点评：业绩稳定高增长，肝肾病产品空间巨大",
                "features": {
                    "keywords": [
                        "东北医药",
                        "崔洁铭",
                        "健帆生物",
                        "300529",
                        "年报",
                        "业绩",
                        "稳定高增长",
                        "肝肾病",
                        "产品",
                        "空间巨大"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}